Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Apogee Therapeutics, Inc. APGE NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$105.63
+19.4%

Apogee Therapeutics, Inc. (APGE) is a Biotechnology company in the Healthcare sector, currently trading at $88.47. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is APGE = $106 (+19.4% upside).

Valuation: APGE trades at a trailing Price-to-Earnings (P/E) of -20 (S&P 500 average ~25).

Net income is $256M (loss), growing at -5.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $9M against $904M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 26.57 (strong liquidity). Debt-to-assets is 0.9%. Total assets: $937M.

Analyst outlook: 9 / 10 analysts rate APGE as buy (90%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$105.63
▲ 19.4% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Apogee Therapeutics, Inc., the average price target is $105.63, with a high forecast of $137.00, and a low forecast of $83.00.
Highest Price Target
$137.00
Average Price Target
$105.63
Lowest Price Target
$83.00

APGE SharesGrow Score Overview

65/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — APGE

✓
VALUE Pass
75/100
APGE trades at a trailing Price-to-Earnings (P/E) of -20 (S&P 500 average ~25). Forward PEG -0.99 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $106, implying +19.8% from the current price $88. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
APGE: +0%/yr revenue is, -5.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet APGE: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 26.57 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
APGE: Gross margin is 0% (+0 pp trend), $5B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 9 / 10 analysts rate APGE as buy (90%). Analyst consensus target is $106 (+19.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range26.2-85.94
Volume555.07K
Avg Volume (30D)1.04M
Market Cap$4.95B
Beta (1Y)1.03
Share Statistics
EPS (TTM)-4.22
Shares Outstanding$60.69M
IPO Date2023-07-14
Employees196
CEOMichael Thomas Henderson
Financial Highlights & Ratios
Gross Profit$-1.42M
EBITDA$-284.18M
Net Income$-255.84M
Operating Income$-285.6M
Total Cash$730.19M
Total Debt$8.85M
Net Debt$-122.7M
Total Assets$937.13M
Price / Earnings (P/E)-21
Analyst Forecast
1Y Price Target$99.00
Target High$137.00
Target Low$83.00
Upside+11.9%
Rating ConsensusBuy
Analysts Covering10
Buy 90% Hold 10% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS03770N1019

Price Chart

Track all markets on TradingView
APGE
Apogee Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
26.20 52WK RANGE 85.94

People Also View

CNTA
CNTA
Centessa Pharmaceuticals plc
$39.59
+0.05%
 CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 CGON
CGON
CG Oncology, Inc. Common stock
$67.28
-0.62%
 XENE
XENE
Xenon Pharmaceuticals Inc.
$59.35
+1.28%
 LEGN
LEGN
Legend Biotech Corporation
$18.69
+5.65%
 SLNO
SLNO
Soleno Therapeutics, Inc.
$52.62
-0.04%
 IRON
IRON
Disc Medicine, Inc.
$70.48
+2.95%
 ZLAB
ZLAB
Zai Lab Limited
$21.96
+2.91%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message